Guang Yang

1 month ago | onlinelibrary.wiley.com | Yang Liu |Xiaofei Jiang |Guang Yang |Shengmin Zhou

Conflicts of Interest The authors declare no conflicts of interest. References 1, , , , and , “Potential Food Applications of Edible Oil Organogels,” Trends in Food Science Technology 20, no. 10 (2009): 470–480. 2, , , et al., “Chemical Profiling of the Major Components in Natural Waxes to Elucidate Their Role in Liquid Oil Structuring,” Food Chemistry 214 (2017): 717–725.

Jan 9, 2025 | mckinsey.com | Guang Yang |Jeff Smith |Lucy Perez |Valentina Sartori

Life sciences is on the cusp of a new era of innovation. The convergence of breakthrough technologies, widespread access to data, and deeper insights into complex biological systems is revolutionizing how the industry approaches R&D. For instance, venture capital funding for machine-learning-enabled drug discovery surged more than sevenfold from 2019 to 2022, according to McKinsey analysis.

Jan 9, 2025 | mckinsey.com | Guang Yang |Jeff Smith

Leading biopharmaceutical companies manage their clinical pipelines to optimize for risk and reward. Here’s how. Discovering and developing effective new medicines has always been difficult—but it is particularly hard today. The world’s biopharmaceutical companies face challenges ranging from rising R&D costs to the evolving impact of the US Inflation Reduction Act, all while focused on delivering innovative solutions for patients.

Jan 9, 2025 | mckinsey.com | Ahsan Saeed |Gaurav Agrawal |Guang Yang |Stephan Wurzer

Leading companies are revamping research and early development to curb lengthy drug development timelines and rising costs. The journey to bring new medicines to market remains long and costly, despite recent technological and process improvements in biopharma R&D. It takes about a decade, on average, from candidate nomination to launch, and study and application costs for investigational new drugs (INDs) have soared in recent years by 20–30 percent.

Dec 10, 2024 | onlinelibrary.wiley.com | Guang Yang |Yuting Wang |Yulin Lv |Benli Song

1 Introduction Mitochondria serve as the energy factories of cells, regulating cellular environmental homeostasis and energy metabolism.[1] The impairment of mitochondrial activity in malignancies could inhibit tumor proliferation, migration, and drug resistance.[2] Therapeutic strategies based on mitochondrial damage have become the focus.[3] Several clinical trials are investigating the potential of inhibiting mitochondrial function as a novel tumor therapy.[4] However, tumors have evolved...